No Data
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $16
JMP Securities analyst Constantine Davides maintains $OptimizeRx(OPRX.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 23.5%
OptimizeRx: A Strong Buy on Client Commitments and Growth Potential
Lake Street Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $15
Lake Street analyst Eric Martinuzzi maintains $OptimizeRx(OPRX.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 40.9% and a
Express News | OptimizeRx Continues to Expand Its Strategic Relationship With a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment With Over $10M in-Year Total Value
OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences
Down -12.46% in 4 Weeks, Here's Why OptimizeRx (OPRX) Looks Ripe for a Turnaround